Ovarian Cancer

Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.

Overview

Feature Articles

Latest Ovarian Cancer News and Research

Scientists create blood test to enhance cancer treatment effectiveness

Scientists create blood test to enhance cancer treatment effectiveness

Global study reveals shifting trends in ovarian cancer incidence by subtype and region

Global study reveals shifting trends in ovarian cancer incidence by subtype and region

Metabolic imaging detects ovarian cancer subtypes and predicts chemotherapy response

Metabolic imaging detects ovarian cancer subtypes and predicts chemotherapy response

Scientists uncover genetic code driving tumor formation and spread

Scientists uncover genetic code driving tumor formation and spread

MRI-based imaging technique predicts the response of ovarian cancer to treatment

MRI-based imaging technique predicts the response of ovarian cancer to treatment

New collaborative effort aims to cure ALK-positive lung cancer

New collaborative effort aims to cure ALK-positive lung cancer

Novel single-cell genomics analysis approach provides direct insights into cell cycle and proliferation

Novel single-cell genomics analysis approach provides direct insights into cell cycle and proliferation

Exploring the potential of MSCs in cancer therapy

Exploring the potential of MSCs in cancer therapy

New gold-based drug proves to be more potent than standard chemotherapy

New gold-based drug proves to be more potent than standard chemotherapy

Study identifies DNA collisions driving genetic changes in cancer

Study identifies DNA collisions driving genetic changes in cancer

Leveraging genetic variations for more effective cancer therapies

Leveraging genetic variations for more effective cancer therapies

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Study identifies 80 genes linked to increased risk of breast cancer

Study identifies 80 genes linked to increased risk of breast cancer

New therapeutic target overcomes ovarian cancer immunotherapy resistance

New therapeutic target overcomes ovarian cancer immunotherapy resistance

New pipeline analyzes drug responses in primary tumors

New pipeline analyzes drug responses in primary tumors

Tiny particles deliver combined heat and chemotherapy to tumors

Tiny particles deliver combined heat and chemotherapy to tumors

FarrSight-Twin technology transforms cancer treatment research

FarrSight-Twin technology transforms cancer treatment research

Researchers identify mechanism of immune suppression in ovarian cancer

Researchers identify mechanism of immune suppression in ovarian cancer

Researchers discover how ovarian tumors cripple immune cells

Researchers discover how ovarian tumors cripple immune cells

New insights on 5-fluorouracil's mechanism in different cancers

New insights on 5-fluorouracil's mechanism in different cancers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.